ArticleJournal of neurology2023
Autoimmune encephalitis: recent clinical and biological advances.
Article in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The evolving etiologies of rapidly progressive dementia: a systematic review.Translational psychiatry · 2025Pooled it
- The cascade to pathogenicity in autoantibody-mediated CNS diseases.Brain : a journal of neurology · 2026Review
- Evaluating the Value of Tissue-Based Assays in the Diagnosis of AE.Revista de neurologia · 2026Article
- Forkhead box versus NF-κB hippocampal snRNA-seq profiles distinguish anti-Drebrin- and anti-GAD65-positive encephalitis.Journal of neuroinflammation · 2026Article
- Article
- High-Affinity Human Germline and Mutated Autoantibodies Commonly Cross-React to Self-Antigens in 5 Subgroups of Autoimmune Encephalitis.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Screening 1021 Swedish memory clinic visitors for autoantibody-mediated encephalitis.Journal of neurology · 2026Article
- Clinical features, outcome and HLA subtypes in Eastern patients with anti-IgLON5 disease: a multicenter study.Orphanet journal of rare diseases · 2026Article
- Study on intravenous immunoglobulin use in a pediatric intensive care unit of a tertiary care center.World journal of clinical pediatrics · 2026Article
- Visual Hallucinations and Cognitive Impairment as the Initial Presentation of Severe Hypothyroidism in an Elderly Patient: A Case Report.Geriatrics (Basel, Switzerland) · 2026Article
- D-serine ameliorates cognitive deficits by preserving neuronal and synaptic function in experimental anti-NMDAR encephalitis.Journal of neuroinflammation · 2026Article
- WONOEP XVII appraisal: The immunopathogenesis of epilepsy.Epilepsia · 2026Review
- Diagnostic challenge of GAD65-associated autoimmune encephalitis mimicking post-traumatic complications in an older adult: a case report.Frontiers in medicine · 2026Article
- Case Report: Sequential FcRn blockade and B-cell depletion for treatment-refractory relapsing autoimmune encephalitis: a three-patient case series.Frontiers in immunology · 2026Article
- Efgartigimod as a salvage therapy for anti-NMDAR encephalitis patients after first-line treatment failure: a case series.Frontiers in neurology · 2026Article
- Multimodal temporal dissociation in anti-GABAFrontiers in immunology · 2026Article
- Brain atrophy in autoimmune encephalitis: epidemiology, pathophysiology, clinical manifestations, treatment, and prognosis-an update.Journal of neurology · 2025Review
- Neuronal surface and intracellular antibody testing in patients with long-term epilepsy.Epilepsia open · 2025Article
- Clinical, Electroencephalogram and Imaging Characteristics of Patients With Anti-LGI1 Antibody Encephalitis: A Multicenter Cohort Study.CNS neuroscience & therapeutics · 2025Article
- Immunotherapy for autoimmune encephalitis.Cell death discovery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In 2015, we wrote a review in The Journal of Neurology summarizing the field of autoantibody-associated neurological diseases. Now, in 2023, we present an update of the subject which reflects the rapid expansion and refinement of associated clinical phenotypes, further autoantibody discoveries, and a more detailed understanding of immunological and neurobiological pathophysiological pathways which mediate these diseases. Increasing awareness around distinctive aspects of their clinical phenotypes has been a key driver in providing clinicians with a better understanding as to how these diseases are best recognized. In clinical practice, this recognition supports the administration of often effective immunotherapies, making these diseases 'not to miss' conditions. In parallel, there is a need to accurately assess patient responses to these drugs, another area of growing interest. Feeding into clinical care are the basic biological underpinnings of the diseases, which offer clear pathways to improved therapies toward enhanced patient outcomes. In this update, we aim to integrate the clinical diagnostic pathway with advances in patient management and biology to provide a cohesive view on how to care for these patients in 2023, and the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.